Quetiapine in adolescents with non-affective psychotic disorders: An open-label trial

Pharmacopsychiatry

Volumn 44, Issue 3, 2011, Pages 87-95

  Holzer, L ^a   Preuss, U ^b   Baumgartner, L ^b   Jaugey, L ^a   Urben, S ^a   Halfon, O ^a   Baumann, P ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b UNIVERSITY OF BERN   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

QUETIAPINE; SERTRALINE;

ADOLESCENT; ADULT; AGGRESSION; ALCOHOL CONSUMPTION; ANXIETY; APPETITE; ARTICLE; CANNABIS SMOKING; CLINICAL ARTICLE; DELUSION; DIZZINESS; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG MONITORING; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HALLUCINATION; HEALTH SERVICE; HUMAN; LEUKOPENIA; MALE; MOOD CHANGE; MORNING DOSAGE; NAUSEA; PATIENT COMPLIANCE; PRIORITY JOURNAL; PSYCHOSIS; QUESTIONNAIRE; RHINITIS; SEDATION; SIDE EFFECT; SOMNOLENCE; SUICIDAL BEHAVIOR; SUICIDAL IDEATION; UPPER ABDOMINAL PAIN; VIOLENCE; WEIGHT GAIN;

ADOLESCENT; ANTI-ANXIETY AGENTS; ANTIDEPRESSIVE AGENTS; ANTIPSYCHOTIC AGENTS; COMORBIDITY; DIBENZOTHIAZEPINES; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MENTAL DISORDERS; PSYCHIATRIC STATUS RATING SCALES; PSYCHOTIC DISORDERS; QUESTIONNAIRES; RESEARCH DESIGN;

EID: 79956124302     PISSN: 01763679     EISSN: 14390795     Source Type: Journal    
DOI: 10.1055/s-0031-1271682     Document Type: Article

References (74)

1. van OSJ, Kapur S. Schizophrenia. Lancet 2009 374 9690 635-645
2. Schimmelmann BG, Conus P, Cotton S et al,. Pre-treatment, baseline, and outcome differences between early-onset and adult-onset psychosis in an epidemiological cohort of 636 first-episode patients. Schizophr Res 2007 95 1-8 (Pubitemid 47315740)
3. Lay B, Blanz B, Hartmann M et al,. The psychosocial outcome of adolescent-onset schizophrenia: a 12-year follow-up. Schizophr Bull 2000 26 801-816
4. Fleischhaker C, Schulz E, Tepper K et al,. Long-term course of adolescent schizophrenia. Schizophr Bull 2005 31 769-780 (Pubitemid 41253325)
5. Ballageer T, Malla A, Manchanda R et al,. Is adolescent-onset first-episode psychosis different from adult onset? J Am Acad Child Adolesc Psychiatry 2005 44 782-789 (Pubitemid 41026282)
6. Pencer A, Addington J, Addington D. Outcome of a first episode of psychosis in adolescence: a 2-year follow-up. Psychiatry Res 2005 133 35-43
7. Fraguas D, Correll CU, Merchan-Naranjo J et al,. Efficacy and safety of second-generation antipsychotics in children and adolescents with psychotic and bipolar spectrum disorders: Comprehensive review of prospective head-to-head and placebo-controlled comparisons. Eur Neuropsychopharmacol 2010 Aug 9
8. Moore TA, Buchanan RW, Buckley PF et al,. The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2006 update. J Clin Psychiatry 2007 68 1751-1762 (Pubitemid 350247505)
9. Kane JM, Leucht S, Carpenter D et al,. The expert consensus guideline series Optimizing pharmacologic treatment of psychotic disorders. J Clin Psychiatry 2003 64 Suppl. 12 4-100
10. van OSJ, Kapur S. Schizophrenia. Lancet 2009 374 9690 635-645
11. Remington G, Kapur S. Atypical antipsychotics: are some more atypical than others? [Review]. Psychopharmacology 2000 148 3-15 (Pubitemid 30062465)
12. Armenteros JL, Davies M. Antipsychotics in early onset Schizophrenia: Systematic review and meta-analysis. Eur Child Adolesc Psychiatry 2006 15 141-148
13. Sikich L, Frazier JA, McClellan J et al,. Double-blind comparison of first- and second-generation antipsychotics in early-onset schizophrenia and schizo-affective disorder: findings from the treatment of early-onset schizophrenia spectrum disorders (TEOSS) study. Am J Psychiatry 2008 165 1420-1431
14. Vitiello B, Correll C, Zwieten-Boot B et al,. Antipsychotics in children and adolescents: Increasing use, evidence for efficacy and safety concerns. Eur Neuropsychopharmacol 2009 May 23
15. Arango C, Parellada M, Moreno DM. Clinical effectiveness of new generation antipsychotics in adolescent patients. Eur Neuropsychopharmacol 2004 S471-S479 (Pubitemid 39574339)
16. Sikich L. Efficacy of atypical antipsychotics in early-onset schizophrenia and other psychotic disorders. J Clin Psychiatry 2008 69 21-25
17. Lieberman JA, Perkins D, Belger A et al,. The early stages of schizophrenia: speculations on pathogenesis, pathophysiology, and therapeutic approaches. Biol Psychiatry 2001 50 884-897 (Pubitemid 34023591)
18. Kumra S, Oberstar JV, Sikich L et al,. Efficacy and tolerability of second-generation antipsychotics in children and adolescents with schizophrenia. Schizophr Bull 2008 34 60-71 (Pubitemid 350262286)
19. Correll CU. Assessing and maximizing the safety and tolerability of antipsychotics used in the treatment of children and adolescents. J Clin Psychiatry 2008 69 26-36
20. McConville BJ, Sorter MT. Treatment challenger and safety considerations for antipsychotic use in chidren and adolescents with psychoses. J Clin Psychiatry 2004 65 Suppl. 6 20-29
21. Mattai AK, Hill JL, Lenroot RK. Treatment of early-onset schizophrenia. Curr Opin Psychiatry 2010 23 304-310
22. Small JG, Hirsch SR, Arvanitis LA et al,. Seroquel Study Group. Quetiapine in patients with schizophrenia: A high- and low-dose double-blind comparison with placebo. Arch Gen Psychiatry 1997 54 549-557 (Pubitemid 27258553)
23. Adityanjee MD, Schulz SC. Clinical use of quetiapine in disease states other than schizophrenia. J Clin Psychiatry 2002 63 32-38 (Pubitemid 35471368)
24. Martinotti G, Andreoli S, Di Nicola M et al,. Quetiapine decreases alcohol consumption, craving, and psychiatric symptoms in dually diagnosed alcoholics. Hum Psychopharmacol 2008 23 417-424
25. Vaishnavi S, Alamy S, Zhang W et al,. Quetiapine as monotherapy for social anxiety disorder: a placebo-controlled study. Prog Neuropsychopharmacol Biol Psychiatry 2007 31 1464-1469 (Pubitemid 47302561)
26. Nemeroff CB, Kinkead B, Goldstein J. Quetiapine: preclinical studies, pharmacokinetics, drug interactions, and dosing. J Clin Psychiatry 2002 63 5-11 (Pubitemid 35471364)
27. 2 receptor occupancy. Arch Gen Psychiatry 2000 57 553-559 (Pubitemid 30349435)
28. 2A receptor occupancy of different doses of quetiapine in schizophrenia: a PET study. Eur Neuropsychopharmacol 2001 11 105-110 (Pubitemid 32335553)
29. DeVane CL, Nemeroff CB. Clinical pharmacokinetics of quetiapine an atypical antipsychotic. Clin Pharmacokinet 2001 40 509-522
30. Winter HR, Earley WR, Hamer-Maansson JE et al,. Steady-state pharmacokinetic, safety, and tolerability profiles of quetiapine, norquetiapine, and other quetiapine metabolites in pediatric and adult patients with psychotic disorders. J Child Adolesc Psychopharmacol 2008 18 81-98 (Pubitemid 351311245)
31. Jensen NH, Rodriguiz RM, Caron MG et al,. N-Desalkylquetiapine, a potent norepinephrine reuptake inhibitor and partial 5-HT1A agonist, as a putative mediator of quetiapine's antidepressant activity. Neuropsychopharmacology 2008 33 2303-2312
32. Findling RL. Use of quetiapine in children and adolescents. J Clin Psychiatry 2002 63 27-31 (Pubitemid 35471367)
33. Cheng-Shannon J, McGough JJ, Pataki C et al,. Second-generation antipsychotic medications in children and adolescents. J Child Adolesc Psychopharmacol 2004 14 372-394 (Pubitemid 39473123)
34. Beer F, Heinrich H, Springer S et al,. Quetiapine in the treatment of psychotic adolescents: a case series of 23 patients with severe early onset psychosis. World J Biol Psychiatry 2007 8 38-41 (Pubitemid 46291200)
35. Schimmelmann BG, Mehler-Wex C, Lambert M et al,. A prospective 12-week study of quetiapine in adolescents with schizophrenia spectrum disorders. J Child Adolesc Psychopharmacol 2007 17 768-778 (Pubitemid 351158602)
36. Bishop JR, Pavuluri MN. Review of risperidone for the treatment of pediatric and adolescent bipolar disorder and schizophrenia. Neuropsychiatr Dis Treat 2008 4 55-68 (Pubitemid 351460980)
37. Coukell AJ, Spencer CM, Benfield P. Amisulpride A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of schizophrenia. CNS Drugs 1996 6 237-256 (Pubitemid 26306854)
38. Roke Y, van Harten PN, Boot AM et al,. Antipsychotic medication in children and adolescents: a descriptive review of the effects on prolactin level and associated side effects. J Child Adolesc Psychopharmacol 2009 19 403-414
39. Castro-Fornieles J, Parellada M, Soutullo CA et al,. Antipsychotic treatment in child and adolescent first-episode psychosis: a longitudinal naturalistic approach. J Child Adolesc Psychopharmacol 2008 18 327-336
40. Correll CU, Kane JM. One-year incidence rates of tardive dyskinesia in children and adolescents treated with second-generation antipsychotics: a systematic review. J Child Adolesc Psychopharmacol 2007 17 647-656
41. Croarkin PE, Emslie GJ, Mayes TL. Neuroleptic malignant syndrome associated with atypical antipsychotics in pediatric patients: a review of published cases. J Clin Psychiatry 2008 69 1157-1165 (Pubitemid 352031600)
42. Jerrell JM, Hwang TL, Livingston TS. Neurological adverse events associated with antipsychotic treatment in children and adolescents. J Child Neurol 2008 23 1392-1399
43. Kuehn BM. FDA panel OKs 3 antipsychotic drugs for pediatric use, cautions against overuse. JAMA 2009 302 833-834
44. Greenspan A, Gharabawi G, Kwentus J. Thyroid dysfunction during treatment with atypical antipsychotics. J Clin Psychiatry 2005 66 1334-1335 (Pubitemid 41546518)
45. Potkin SG, Gharabawi GM, Greenspan AJ et al,. A double-blind comparison of risperidone, quetiapine and placebo in patients with schizophrenia experiencing an acute exacerbation requiring hospitalization. Schizophr Res 2006 85 254-265 (Pubitemid 43947539)
46. Kontaxakis VP, Karaiskos D, Havaki-Kontaxaki BJ et al,. Can quetiapine-induced hypothyroidism be reversible without quetiapine discontinuation? Clin Neuropharmacol 2009 32 295-296
47. Fraguas D, Merchan-Naranjo J, Laita P et al,. Metabolic and hormonal side effects in children and adolescents treated with second-generation antipsychotics. J Clin Psychiatry 2008 69 1166-1175 (Pubitemid 352031601)
48. Simon V, van WR, de HM. Are weight gain and metabolic side effects of atypical antipsychotics dose dependent? A literature review. J Clin Psychiatry 2009 70 1041-1050
49. Bolognini M, Plancherel B, Laget J et al,. Evaluation of the adolescent drug abuse diagnosis instrument in a Swiss sample of drug abusers. Addiction 2001 96 1477-1484 (Pubitemid 32977086)
50. Kay SR, Opler LA, Lindenmayer JP. The positive and negative syndrome scale (PANSS): rationale and standardisation. Br J Psychiatry 1989 155 suppl 7 59-65 (Pubitemid 19270851)
51. Guy W. ECDEU Assessment Manual for Psychopharmacology. Washington, DC Department of Health, Education and Welfare 1976
52. Simpson GM, Angus JW. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl 1970 212 11-19
53. Barnes TR. A rating scale for drug-induced akathisia. Br J Psychiatry 1989 154 672-676 (Pubitemid 19154942)
54. Le Bloch Y, Baumann P, Stigler M et al,. Efficacy and tolerability of quetiapine in cluster B personality disorder: an open-label study. Int J Psychiatry Clin Pract 2007 11 123-128 (Pubitemid 46763606)
55. Cole TJ. A chart to link child centiles of body mass index, weight and height. Eur J Clin Nutr 2002 56 1194-1199 (Pubitemid 36124408)
56. Farpour-Lambert N, LAllemand D, Laimbacher J. Définition, diagnostic et indications thérapeutiques de la surcharge pondérale de lenfant et de ladolescent. Paediatrica 2006 17 19-24
57. Berger GE, Proffitt TM, McConchie M et al,. Dosing quetiapine in drug-naive first-episode psychosis: a controlled, double-blind, randomized, single-center study investigating efficacy, tolerability, and safety of 200mg/day vs. 400mg/day of quetiapine fumarate in 141 patients aged 15 to 25 years. J Clin Psychiatry 2008 69 1702-1714
58. Haas M, Unis AS, Armenteros J et al,. A 6-week, randomized, double-blind, placebo-controlled study of the efficacy and safety of risperidone in adolescents with schizophrenia. J Child Adolesc Psychopharmacol 2009 19 611-621
59. Findling RL, Robb A, Nyilas M et al,. A multiple-center, randomized, double-blind, placebo-controlled study of oral aripiprazole for treatment of adolescents with schizophrenia. Am J Psychiatry 2008 165 1432-1441
60. Takahashi H, Oshimo T, Ishigooka J. Efficacy and tolerability of aripiprazole in first-episode drug-naive patients with schizophrenia: an open-label trial. Clin Neuropharmacol 2009 32 149-150
61. Lee HY, Ham BJ, Kang RH et al,. Trial of aripiprazole in the treatment of first-episode schizophrenia. Psychiatry Clin Neurosci 2010 64 38-43
62. Larsen TK, Melle I, Auestad B et al,. Substance abuse in first-episode non-affective psychosis. Schizophr Res 2006 88 55-62 (Pubitemid 44693253)
63. Addington J, Addington D. Patterns, predictors and impact of substance use in early psychosis: a longitudinal study. Acta Psychiatr Scand 2007 115 304-309 (Pubitemid 46425747)
64. McConville BJ, Arvanitis LA, Thyrum PT et al,. Pharmacokinetics, tolerability, and clinical effectiveness of quetiapine fumarate: an open-label trial in adolescents with psychotic disorders. J Clin Psychiatry 2000 61 252-260 (Pubitemid 30305366)
65. 2 receptors: an explanation for low receptor occupancy and early clinical relapse upon withdrawal of clozapine or quetiapine. Am J Psychiatry 1999 156 876-884 (Pubitemid 29260342)
66. 2 receptor explain the action of atypical antipsychotics?: a new hypothesis. Am J Psychiatry 2001 158 360-369 (Pubitemid 32205190)
67. Connor DF, McLaughlin TJ, Jeffers-Terry M. Randomized controlled pilot study of quetiapine in the treatment of adolescent conduct disorder. J Child Adolesc Psychopharmacol 2008 18 140-156 (Pubitemid 351591434)
68. Duffy A, Milin R, Grof P. Maintenance treatment of adolescent bipolar disorder: open study of the effectiveness and tolerability of quetiapine. BMC Psychiatry 2009 9 4
69. Gerlach M, Hunnerkopf R, Rothenhofer S et al,. Therapeutic drug monitoring of quetiapine in adolescents with psychotic disorders. Pharmacopsychiatry 2007 40 72-76 (Pubitemid 46697678)
70. Hasselstrøm J, Linnet K. Quetiapine serum concentrations in psychiatric patients The influence of comedication. Ther Drug Monit 2004 26 486-491 (Pubitemid 39314315)
71. Bachmann CJ, Haberhausen M, Heinzel-Gutenbrunner M et al,. Large intraindividual variability of olanzapine serum concentrations in adolescent patients. Ther Drug Monit 2008 3 108-112 (Pubitemid 351161108)
72. Aichhorn W, Marksteiner J, Walch T et al,. Influence of age, gender, body weight and valproate comedication on quetiapine plasma concentrations. Int Clin Psychopharmacol 2006 21 81-85 (Pubitemid 43740314)
73. Pichini S, Papaseit E, Joya X et al,. Pharmacokinetics and therapeutic drug monitoring of psychotropic drugs in pediatrics. Ther Drug Monit 2009 31 283-318
74. Mehler-Wex C, Kolch M, Kirchheiner J et al,. Drug monitoring in child and adolescent psychiatry for improved efficacy and safety of psychopharmacotherapy. Child Adolesc Psychiatry Ment Health 2009 3 14